By Ekta Batra Jan 4, 2022 1:57:09 PM IST (Updated)
Alembic Pharma is in focus as the company has got the final US Food & Drug Administration (USFDA) approval for Doxycycline Hyclate Delayed-Release Tablets. It is a drug that is used to treat drug-resistant bacteria. Its market size is quite small so it is around $10 million in terms of total market size, but nonetheless, it adds to their kitty in terms of approvals when it comes to the US markets.
Alembic Pharma is in focus as the company has got the final US Food & Drug Administration (USFDA) approval for Doxycycline Hyclate Delayed-Release Tablets. It is a drug that is used to treat drug-resistant bacteria. Its market size is quite small so it is around $10 million in terms of total market size, but nonetheless, it adds to their kitty in terms of approvals when it comes to the US markets.
Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.